Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Aptevo Therapeutics Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +3 vs. Q2 2023
- Shares held
- 3.41M
- +2.48M (+267.1%) vs. Q2 2023
- Total value
- $1.13M
- −$234.0K (−17.2%) vs. Q2 2023
- New holders
- 5
- 4 more added
- Sold out
- 2
- 5 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 1,334,169 | $440.3K | 1.39% | +1,334,169 | New |
| Armistice Capital, LLC | 1,235,000 | $407.6K | 0.01% | +1,235,000 | New |
| Vanguard Group Inc | 221,064 | $73.0K | 0.00% | −7,760−3.4% | Reduced |
| Renaissance Technologies LLC | 175,980 | $58.0K | 0.00% | +95,794+119.5% | Added |
| Schonfeld Strategic Advisors LLC | 142,800 | $47.1K | 0.00% | −1,800−1.2% | Reduced |
| Geode Capital Management, LLC | 75,355 | $24.9K | 0.00% | +22,530+42.7% | Added |
| Cantor Fitzgerald, L. P. | 56,354 | $18.6K | 0.00% | −194,768−77.6% | Reduced |
| Price T Rowe Associates Inc | 46,200 | $16.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 47,668 | $15.7K | 0.00% | −378−0.8% | Reduced |
| Northern Trust Corp | 14,121 | $4.66K | 0.00% | −3,521−20.0% | Reduced |
| Tower Research Capital LLC (TRC) | 13,495 | $4.45K | 0.00% | +12,005+805.7% | Added |
| Morgan Stanley | 11,013 | $3.63K | 0.00% | 00.0% | Unchanged |
| Franklin Resources Inc | 10,997 | $3.63K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 10,941 | $3.61K | 0.00% | 00.0% | Unchanged |
| Divergent Wealth Advisors, LLC | 10,000 | $3.30K | 0.00% | +10,000 | New |
| JPMorgan Chase & Co | 1,907 | $629 | 0.00% | +1,907 | New |
| Wells Fargo & Company | 1,562 | $515 | 0.00% | +31+2.0% | Added |
| Fifth Third Bancorp | 291 | $96 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 142 | $47 | 0.00% | 00.0% | Unchanged |
| Truvestments Capital LLC | 95 | $31 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 85 | $28 | 0.00% | +85 | New |
| Advisor Group Holdings, Inc. | 30 | $9 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 17 | $6 | 0.00% | 00.0% | Unchanged |
| Earnest Partners LLC | 14 | $5 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 10 | $3 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 6 | $2 | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −12,782−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |